IMMUNETHEP is a biotechnology company created in 2013 as a spin-off of the University of Porto.
The company was founded by Pedro Madureira (CSO), who brought the scientific knowledge, and Venture Catalysts, specialists in technology commercialization. IMMUNETHEP’s CEO, Bruno Santos, was previously a Partner at Venture Catalysts.
IMMUNETHEP embraced the technology initially developed at the Laboratory of Immunology of ICBAS, where Pedro Madureira was part of the R&D team, and has been further developing it and exploring its possibilities.
In 2015 the company established its HQ and R&D facilities in Cantanhede, Portugal, at the Biocant Park, where it has been expanding ever since.
Over the years IMMUNETHEP has seen its potential recognized through several awards and prizes (e.g. Premio Empreendedor XXI by CaixaBank in 2018), investment rounds and partnerships with prestigious institutions and top pharma companies.
Portugal Ventures was founded in 2012 to drive the global success of Portuguese companies, helping them achieve competitiveness goals in all stages of development.
Portugal Ventures is the leading Venture Capital investor in life sciences in Portugal and first invested in IMMUNETHEP in 2015.
The Venture Catalysts are specialized in shaping science into business and technology commercialization. The company was founded in 2010 and supports researchers/entrepreneurs with science grounded ideas to build and develop technology based companies into the market.
Venture Catalysts have co-founded IMMUNETHEP in 2013 and Bruno Santos is the company’s CEO since then.
Would you like to join a young, passionate, committed and enthusiastic team?
Come on board and help building a safer tomorrow!
Drop us an email: email@example.com